Blocking a tumor protein helped mice with a hard to treat brain tumor
Original title: Targeting Tumor-derived Sphingosine Kinase 2 Unleashes Antitumor Immunity and Improves Survival of Mice with Group 3 Medulloblastoma
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was only done in mice, not in people.
The short version
In mice, blocking one protein made the tumor easier for the immune system to fight.
What was studied. Researchers studied Group 3 medulloblastoma, the type of medulloblastoma with the worst outlook. They tested a drug called Opaganib in mice, alone and along with small repeated doses of radiation.
What they found. The tumors made a protein called SPHK2. It held back immune cells that attack tumors and let other cells calm the immune response down. Blocking SPHK2 turned the immune attack back on, and the mice lived longer. Adding the small repeated doses of radiation helped the mice live longer still, without serious harm from the treatment.
What this means, and what it doesn't
What it could mean: This points to a new target in a tumor type that has few options today. The drug used already exists, so researchers can keep testing this idea.
What it doesn't mean: This does not mean there is a new treatment for people. The work was done only in mice. Many things that help mice do not help people. No one has tested this plan in patients yet, so it is not a cure and it is a long way from everyday care.
Source: bioRxiv (preprint), August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.